Nintedanib Combination Delayed Progression in Malignant Mesothelioma

Adding nintedanib to pemetrexed/cisplatin improved the progression-free survival of patients with malignant pleural mesothelioma compared with placebo.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Lung Cancer News Source Type: news